Flush With Fresh Funds, ReViral CEO Outlines RSV Trial Plans

01 Aug 2018

• By Sten Stovall

Biotech's CEO says its lead respiratory candidate RV521 has 'caught up with rivals' in efficacy and safety.

SC1808_Sick Boy_730035700_1200.jpg — ReViral to test RV521 in babies aged one to 24 months. • Source: Shutterstock

More from Financing

More from Business